TWST — Twist Bioscience Corporation stock price, charts and financials

QT67Twist Bioscience Corporation

Twist Bioscience Corporation (NASDAQ: TWST) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
155.56
+12.49+8.73%
OverviewShort InterestFilings
TWSTQT67Twist Bioscience Corporation·NASDAQ
155.56+8.73%
News
Up 8.7% — Twist Bioscience (TWST) Is Up 14.0% After Lilly AI Drug Discovery Tie-Up Is Announced - Has The Bull Case Changed? (Yahoo).
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
KYMR+1.85%$118.48TXG+5.90%$76.97ARWR+2.96%$67.74KRYS+0.62%$338.75PTGX+0.60%$143.70NUVL+0.00%$123.96CRNX+0.00%$84.95IBRX+6.95%$8.46
Snapshot
Index-P/E-EPS (ttm)-2.22Insider Own4.09%Shs Outstand62.27MPerf Week22.63%
Market Cap9.69BForward P/E-EPS next Y-1.37Insider Trans-22.10%Shs Float59.69MPerf Month33.99%
Enterprise Value9.61BPEG-EPS next Q-0.44Inst Own126.08%Short Float20.21%Perf Quarter87.72%
Income-137.00MP/S22.42EPS this Y2.77%Inst Trans-Short Ratio6.72Perf Half Y249.89%
Sales432.00MP/B21.72EPS next Y36.58%ROA-20.33%Short Interest12.07MPerf YTD390.42%
Book/sh7.16P/C58.01EPS next 5Y-ROE-29.89%52W High163.70 -4.97%Perf Year474.45%
Cash/sh2.68P/FCF-EPS past 3/5Y-ROIC-24.57%52W Low23.30 567.64%Perf 3Y576.64%
Dividend Est.-EV/EBITDA-Sales past 3/5Y22.72% 33.17%Gross Margin51.97%Volatility7.66% 7.14%Perf 5Y31.93%
Dividend TTM-EV/Sales22.25EPS Y/Y TTM38.33%Oper. Margin-31.91%ATR (14)10.03Perf 10Y-
Dividend Ex-Date-Quick Ratio2.38Sales Y/Y TTM38.02%Profit Margin-31.66%RSI (14)68.40Recom2.29
Dividend Gr. 3/5Y-Current Ratio2.67EPS Q/Q-7.58%SMA2013.00%Beta2.18Target Price116.33
Payout0.00%Debt/Eq0.29Sales Q/Q22.92%SMA5033.14%Rel Volume1.94Prev Close143.07
Employees979LT Debt/Eq0.26EarningsNov 13SMA200125.45%Avg Volume1.74MPrice155.56
IPO DateOct 31, 2018Option/ShortYes / YesEPS/Sales Surpr.-48.72% 2.85%Net Debt/EBITDA0.22Volume3,365,442Change8.73%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-17-26ReiteratedLeerink PartnersOutperform$110 → $160
Sep-09-26InitiatedUBSNeutral$89 → $144
Aug-05-26ReiteratedPiper SandlerOverweight$85 → $115
Aug-04-26ReiteratedRobert W. Baird$113 → $115
Jul-16-26ReiteratedLeerink PartnersOutperform$80 → $110
Jul-14-26ReiteratedCanaccord GenuityBuy$90 → $120
Jul-06-26DowngradeEvercore ISI GroupOutperform → In Line$52 → $102
Jun-29-26ReiteratedGuggenheimBuy$60 → $107
Jun-24-26ReiteratedBarclaysOverweight$65 → $95
Jun-15-26ReiteratedCowen & Co.Outperform$68 → $89
Latest News· Times ET
Sep-17-26
Sep-17-2606:10AM
Twist Bioscience (TWST) Is Up 14.0% After Lilly AI Drug Discovery Tie-Up Is Announced - Has The Bull Case Changed?Yahoo
Sep-16-26
Sep-16-2606:59AM
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystembenzinga.com
05:00AM
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discoverygurufocus.com
Sep-09-26
Sep-09-2611:50PM
AI And Robotics In 2026: 16 Recent Developments For InvestorsSeekingAlpha
07:34AM
AI & Robotics in 2026: 16 Recent Developments for Investorsetftrends.com
04:00AM
Twist Bioscience to Present at Baird 2026 Global Healthcare Conferencebusinesswire.com
Sep-03-26
Sep-03-2608:05AM
The Market May Be Telling Us We're Entering A Capital Formation CycleSeekingAlpha
Aug-24-26
Aug-24-2611:55PM
Brandywine Managers LLC Invests $2.16 Million in Twist Bioscience Corporation $TWSTdefenseworld.net
12:19AM
90,053 Shares in Twist Bioscience Corporation $TWST Acquired by Deutsche Bank AGdefenseworld.net
Aug-20-26
Aug-20-2612:36PM
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now)seekingalpha.com
Aug-19-26
Aug-19-2612:11PM
Twist Bioscience Stock Resilient Despite Scorpion Capital Short Reportbenzinga.com
Aug-14-26
Aug-14-2601:00AM
Alger Small Cap Growth Fund Q2 2026 Portfolio ReviewSeekingAlpha
Aug-11-26
Aug-11-2610:00AM
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)247wallst.com
Aug-10-26
Aug-10-2603:22PM
Recursion Pharmaceuticals: I'm Still Bearish Despite Recent Genentech NewsSeekingAlpha
Aug-07-26
Aug-07-2604:28PM
Is Twist Bioscience Corp (TWST) Overvalued After 6.0% Rally? GF Value Says Overvaluedgurufocus.com
Company

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

Ownership
Total institutional ownership126.08%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
9/30/2025
FY 2024
9/30/2024
FY 2023
9/30/2023
FY 2022
9/30/2022
FY 2021
9/30/2021
FY 2020
9/30/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue432377313——————
Cost of Goods Sold Incl. D&A208186180——————
Gross Profit224191133——————
Selling, General and Administrative Excl. Other291247218——————
Research and Development728091——————
Other Operating Expense0045——————
Operating Income-138-136-221——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)35913——————
Net Income Before Taxes-136-77-208——————
Income Taxes011——————
Consolidated Net Income-137-78-209——————
Net Income From Continuing Operations-136-78-209——————
Net Income-137-78-209——————
EPS (Recurring)-2.22-1.30-3.60——————
EPS (Basic, Before Extraordinaries)-2.22-1.30-3.60——————
EPS (Diluted)-2.22-1.30-3.60——————
EBITDA-108-52-177——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio22.334.488.37——————
Gross Margin51.8550.6642.49——————
Operating Margin-31.94-36.07-70.61——————
Net Margin-31.71-20.69-66.77——————
Shares Outstanding626058——————
Market Capitalization9,6451,6882,620——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$175.27$132.56$89.86$47.16$4.45● Close Price0.00M10.30M20.60M30.90M41.20MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Leproust Emily M.Chief Executive OfficerSep 08 '26Sale122.622,302282,280768,427Sep 10
Green PaulaSVP of Human ResourcesSep 08 '26Sale122.62907111,220117,014Sep 10
Cho DennisSee RemarksSep 08 '26Sale122.6241250,52173,651Sep 10
WERNER ROBERT F.Chief Accounting OfficerSep 08 '26Sale122.6223829,18544,399Sep 10
Leproust Emily M.Chief Executive OfficerAug 25 '26Sale151.9841,5706,317,759770,729Aug 27
WERNER ROBERT F.Chief Accounting OfficerAug 24 '26Sale140.77854120,22044,637Aug 25
WERNER ROBERT F.Chief Accounting OfficerAug 21 '26Sale139.0766993,03545,491Aug 25
Cho DennisSee RemarksAug 21 '26Sale139.071,598222,22774,063Aug 25
Finn Patrick JohnPresident and COOAug 21 '26Sale139.074,046562,661210,802Aug 25
Green PaulaSVP of Human ResourcesAug 21 '26Sale139.071,360189,130117,921Aug 25
Laponis AdamChief Financial OfficerAug 21 '26Sale139.071,965273,265108,633Aug 25
Leproust Emily M.Chief Executive OfficerAug 21 '26Sale139.076,639923,259812,299Aug 25
Cho DennisSee RemarksAug 19 '26Sale129.7514,2051,843,09975,661Aug 21
Finn Patrick JohnPresident and COOAug 18 '26Option Exercise67.8523,3551,584,637293,033Aug 20
Finn Patrick JohnPresident and COOAug 18 '26Sale117.6478,3559,217,606214,678Aug 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.